IP Library Granted Patent US 8,465,749
Granted Patent B2
US 8,465,749 · App. 13/243,480 · Granted Jun 18, 2013

Polysaccharide-protein conjugate vaccines

Inventors: Che-Hung Robert Lee (Silver Spring, MD); Carl E. Frasch (Martinsburg, WV)
Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,465,749
App. No.
13/243,480
Granted
Jun 18, 2013
Kind
B2
Abstract

Methods for synthesis and manufacture of polysaccharide-protein conjugate vaccines at high yield are provided. The methods involve reaction of a hydrazide group on one reactant with an aldehyde or cyanate ester group on the other reactant. The reaction proceeds rapidly with a high conjugation efficiency, such that a simplified purification process can be employed to separate the conjugate product from the unconjugated protein and polysaccharide and other small molecule by-products.

Claims (13)

1. A method for preparing a conjugate vaccine, the method comprising:

reacting a polysaccharide with 1-cyano-4-dimethylammoniumpyridinium tetrafluoroborate, whereby a solution of a cyanate-activated polysaccharide is obtained;

reacting a protein with hydrazine or adipic acid dihydrazide in the presence of 1-[3-(dimethylamino)propyl]-3-ethyl carbodiimide hydrochloride at a pH of from 6 to 7, whereby a solution of a hydrazide-activated protein is obtained;

raising the pH of the solution of the hydrazide-activated protein to from 7.0 to 11;

buffer exchanging the solution of the hydrazide-activated protein to a pH of from 10.0 to 11.0;

reacting the cyanate-activated polysaccharide with the hydrazide-activated protein at a pH of from 6 to 8 to yield a conjugate vaccine capable of stimulating an immune response.

2. The method according to claim 1 , wherein the step of reacting the cyanate-activated polysaccharide with the hydrazide-activated protein is conducted in the absence of a blocking agent.

3. The method according to claim 1 , wherein the polysaccharide is selected from the group consisting of Meningococcal polysaccharides, Pneumococcus polysaccharides, Hemophilus influenzae type b polysaccharide, Vi polysaccharide of Salmonnella typhi , and group B Streptococcus polysaccharides .

4. The method according to claim 1 , wherein the protein is selected from the group consisting of tetanus toxoid, diptheria toxoid, CRM 197 , and meningococcal protein.

5. The method of claim 1 , wherein reacting the cyanate-activated polysaccharide with the hydrazide-activated protein is conducted at a temperature of from 0° C. to 5° C. for 36 to 48 hours, followed by an additional 18 to 24 hours at a temperature of from 20° C. to 25° C.

6. The method of claim 1 , wherein the solution of the hydrazide-activated protein is buffer-exchanged at a pH of 10.5.

7. The method of claim 1 , wherein the solution of the hydrazide-activated protein is buffer-exchanged at a pH of 11.

8. The method of claim 1 , wherein the solution of the hydrazide-activated protein is buffer-exchanged with a buffer concentration of 3 mM to 10mM.

Continuity (3)
Division 10566899
Provisional Application 60493389 · Aug 6, 2003
Related Publication 20120076817A1 · Mar 29, 2012